Cancer cell‑specific anticancer effects of Coptis�chinensis on gefitinib‑resistant lung cancer cells are mediated through the suppression of Mcl‑1 and Bcl‑2

Kim, Jaehwan; Ko, Eun Sun; Kim, Dasom; Park, Seong‐Hee; Kim, Eun‐Jung; Rho, Jinkyung; Seo, Hyemin; Kim, Min Jung; Yang, Woong Mο; Ha, In-Joong; Park, Myung‐Jin; Lee, Ji‐Yun

doi:10.3892/ijo.2020.5025

Cited by 4 publications

(4 citation statements)

References 31 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EGFR tyrosine kinase inhibitor (TKI), gefitinib, is used in the treatment of NSCLC with EGFR mutations ( Rawluk and Waller, 2018 ). C. Rhizoma extracts suppress EGFR/AKT signaling and the expression of overexpressed antiapoptotic proteins, Mcl-1 and Bcl-2 in gefitinib-resistant NSCLC cells ( Kim et al, 2020 ).…”

Section: Combination Therapymentioning

confidence: 99%

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Chen

Liang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer is a serious disease with an increasing number of reported cases and high mortality worldwide. Gastrointestinal cancer defines a group of cancers in the digestive system, e.g., liver cancer, colorectal cancer, and gastric cancer. Coptidis Rhizoma (C. Rhizoma; Huanglian, in Chinese) is a classical Chinese medicinal botanical drug for the treatment of gastrointestinal disorders and has been shown to have a wide variety of pharmacological activity, including antifungal, antivirus, anticancer, antidiabetic, hypoglycemic, and cardioprotective effects. Recent studies on C. Rhizoma present significant progress on its anticancer effects and the corresponding mechanisms as well as its clinical applications. Herein, keywords related to C. Rhizoma, cancer, gastrointestinal cancer, and omics were searched in PubMed and the Web of Science databases, and more than three hundred recent publications were reviewed and discussed. C. Rhizoma extract along with its main components, berberine, palmatine, coptisine, magnoflorine, jatrorrhizine, epiberberine, oxyepiberberine, oxyberberine, dihydroberberine, columbamine, limonin, and derivatives, are reviewed. We describe novel and classic anticancer mechanisms from various perspectives of pharmacology, pharmaceutical chemistry, and pharmaceutics. Researchers have transformed the chemical structures and drug delivery systems of these components to obtain better efficacy and bioavailability of C. Rhizoma. Furthermore, C. Rhizoma in combination with other drugs and their clinical application are also summarized. Taken together, C. Rhizoma has broad prospects as a potential adjuvant candidate against cancers, making it reasonable to conduct additional preclinical studies and clinical trials in gastrointestinal cancer in the future.

show abstract

Section: Combination Therapymentioning

confidence: 99%

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Chen

Liang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Kim et al investigated the effects of natural extracts of Coptis chinensis on gefitinib-resistant LC cells. The treatment with extracts alone and combination treatment with gefitinib enhanced the sensitivity of gefitinib-resistant cells to gefitinib in vitro, although no significant improvements were observed in vivo [95].…”

Section: C2 Ceramide Induces Apoptosis and Cell Cycle Arrest In Lc Cellsmentioning

confidence: 90%

Zebrafish in Lung Cancer Research

Wu,

Hua,

et al. 2023

Cancers

View full text Add to dashboard Cite

Zebrafish is increasingly used as a model organism for cancer research because of its genetic and physiological similarities to humans. Modeling lung cancer (LC) in zebrafish has received significant attention. This review focuses on the insights gained from using zebrafish in LC research. These insights range from investigating the genetic and molecular mechanisms that contribute to the development and progression of LC to identifying potential drug targets, testing the efficacy and toxicity of new therapies, and applying zebrafish for personalized medicine studies. This review provides a comprehensive overview of the current state of LC research performed using zebrafish, highlights the advantages and limitations of this model organism, and discusses future directions in the field.

show abstract

“…Experiments proved that Chinese herbal medicine and its extracts can inhibit the growth of tumor cells or prevent the occurrence and development of tumors in various ways. TCM, such as Rhizoma Dioscorea, [26] Rhizoma Arisaematis, [27] Bombyx Batryticatus, [28] Coptis Chinensis, [29] Fructus Lycii, [30,31] Cyathula Officinalis, [32] Astragalus Membranaceus, [33][34][35] Phellodenron Amurense, [36] Cornus officinalis, [37] Gastrodiiae Elata, [38] Ziziphus Jujuba, [39] Polygala Tenuifolia, [40] and Eclipta Prostrata [41] have been confirmed the effect of antitumor. Berberine, the extract of Rhizoma Coptidis, can directly induce apoptosis.…”

Section: Discussionmentioning

confidence: 99%

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis

Qin

et al. 2023

Medicine

View full text Add to dashboard Cite

Rationale: The morbidity and mortality of lung cancer rank the first among all kinds of cancer. In China, anaplastic lymphoma kinase-positive pulmonary tumors account for nearly 5% of non-small cell lung cancer (NSCLC), and these patients are quite likely to develop brain metastases, as high as around 45%. Although anaplastic lymphoma kinase-tyrosine kinase inhibitors crizotinib and alectinib have proved effective for controlling tumor metastases to the brain, drug resistance and disease progression cannot be ignored in the course of treatment. Patient concerns: Most of the literature reports that traditional Chinese medicine (TCM) has produced satisfactory results in the treatment of cancer patients as an adjuvant treatment for various malignancies in a 53-year-old male patient who developed advanced NSCLC with brain metastases. As first-line crizotinib and erlotinib treatments were ineffective and the intracranial lesions progressed extensively, the patient chose to receive TCM treatment alone in the hope of prolonging his life and improving his quality of life. Diagnoses: A 53-year-old male patient who developed advanced NSCLC with brain metastasis. Because first-line crizotinib and alectinib have failed, and the intracranial lesions progressed in a large area. Interventions: The patient requested that the final therapeutic strategy be Chinese medicine as monotherapy for long-term treatment. The patient took 30 mL of the decoction 1 hour after a meal, 3 times a day. The patient was not treated with dehydrating agents or diuretics during the TCM treatment. Outcomes: The improvement was obvious after 3 months of treatment, and significant reduction of cranial lesions. During the follow-up period, the patient developed neither severe liver damage nor kidney damage. Lessons: This case is the first 1 in the world where TCM was introduced as monotherapy for severe conditions with extensive brain metastases and achieved remarkable efficacy.

show abstract

Cancer cell‑specific anticancer effects of Coptis�chinensis on gefitinib‑resistant lung cancer cells are mediated through the suppression of Mcl‑1 and Bcl‑2

Cited by 4 publications

References 31 publications

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Zebrafish in Lung Cancer Research

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis

Contact Info

Product

Resources

About